Kenvue Inc. is an American consumer health company that emerged as an independent entity after being spun off from Johnson & Johnson’s Consumer Healthcare division. It was officially named Kenvue in September 2022 and became fully independent in August 2023, marking a historic shift in the consumer health industry[1][2][3]. Headquartered in Skillman, New Jersey, with plans to relocate to Summit, New Jersey, Kenvue employs around 22,200 people as of 2022[1]. Kenvue owns a portfolio of iconic, trusted brands including Aveeno, Band-Aid, Benadryl, Johnson’s, Listerine, Neutrogena, Tylenol, and Zyrtec, serving approximately 1.2 billion people globally[1][4]. These brands have a heritage of over 135 years backed by extensive research and development, focusing on innovative, science-backed consumer health solutions[3][4]. The company's mission centers on delivering everyday care that improves health outcomes and enriches lives worldwide. The company’s spin-off was a significant business event, highlighted by its IPO in May 2023, which raised $3.8 billion and was the largest U.S. IPO since 2021, with an initial valuation of about $41 billion[1][5]. Initially, Johnson & Johnson retained over 90% ownership but completed full separation through a share exchange by July 2023, after which Kenvue was added to the S&P 500 Dividend Aristocrats index[1][2]. Kenvue’s leadership initially included CEO Thibaut Mongon until his termination in 2025, after which Kirk Perry took over as interim CEO[1]. The company has faced challenges, including a securities class action in 2023 over alleged misleading disclosures related to phenylephrine risks, affecting its stock performance[1]. Notably, the name "Kenvue" symbolizes a fusion of knowledg